Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AKR1C3 | P42330 | 1/20 | 0.39 |
| ▸ | FPR2 | P25090 | 15/20 | 0.37 |
| ▸ | FPR1 | P21462 | 8/20 | 0.37 |
| ▸ | ROCK2 | O75116 | 3/20 | 0.34 |
| ▸ | CDK4 | P11802 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20038031 | 0.80 | PIM1 (0.39) | AKR1C3FPR2FPR1 | |
| SCHEMBL18955175 | 0.80 | FPR2 (0.45) | FPR2FPR1 | |
| SCHEMBL18955177 | 0.80 | FPR2 (0.45) | FPR2FPR1 | |
| SCHEMBL18955245 | 0.80 | FPR2 (0.45) | FPR2FPR1 | |
| SCHEMBL14171455 | 0.78 | DRD2 (0.46) | FPR2FPR1ROCK2 | |
| SCHEMBL14171465 | 0.77 | DRD2 (0.42) | FPR2FPR1ROCK2 | |
| SCHEMBL14171468 | 0.76 | CA12 (0.45) | FPR2FPR1ROCK2 | |
| SCHEMBL18964487 | 0.76 | FPR2 (0.43) | FPR2FPR1 | |
| SCHEMBL28377662 | 0.76 | FPR2 (0.43) | FPR2FPR1 | |
| SCHEMBL30133743 | 0.76 | FPR2 (0.43) | FPR2FPR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180161329-A1 | PYRIDO[3,4-D]PYRIMIDINE DERIVATIVE AND PHARMACEUTICALLY ACCEPTABLE SALT THEREOF | TEIJIN PHARMA LIMITED (JP) | 2018-06-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180161329-A1 | PYRIDO[3,4-D]PYRIMIDINE DERIVATIVE AND PHARMACEUTICALLY ACCEPTABLE SALT THEREOF | CDK4, CDK6, CDK16 | AKR1C3 2289/4885FPR2 4846/4885FPR1 4774/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.